Over the past two decades, many magnetic resonance spectroscopy (MRS) studies reported lower N-acetylaspartate (NAA) in key brain regions of patients with schizophrenia (SZ) compared to healthy subjects. A smaller number of studies report no difference in NAA. Many sources of variance may contribute to these discordant results including heterogeneity of the SZ subject populations and methodological differences such as MRS acquisition parameters, and post-acquisition analytic methods. The current study reviewed proton MRS literature reporting measurements of NAA in SZ with a focus on methodology. Studies which reported lower NAA were significantly more likely to have used longer echo times (TEs), while studies with shorter TEs reported no concentration difference. This suggests that NAA quantitation using MRS was affected by the choice of TE, and that published MRS literature reporting NAA in SZ using a long TE is confounded by apparent differential T 2 relaxation effects between SZ and healthy control groups. Future MRS studies should measure T 2 relaxation times. This would allow for spectral concentration measurements to be appropriately corrected for these relaxation effects. In addition, as metabolite concentration and T 2 relaxation times are completely independent variables, this could offer distinct information about the metabolite of interest.
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Introduction
Spatially resolved magnetic resonance spectroscopy (MRS) has proved to be a powerful and non-invasive tool for the investigation of the neurochemistry of the working healthy and pathological brain. MRS has been used as an investigational tool in schizophrenia (SZ) research following the development of spatially selective pulse sequences and water suppression techniques in the late 1980s which enabled the in vivo detection of brain metabolite resonances.
One brain metabolite commonly examined in MRS studies is N-acetylaspartate (NAA). NAA is a free amino acid that is biosynthesized in neuronal mitochondria. It is found almost exclusively in neurons, including axons and dendrites, and is considered a marker for neuronal viability and integrity. Changes in NAA concentrations could be caused by changes in neuronal density or neuronal dysfunction (such as changes in glucose metabolism or mitochondrial function). A number of proton MRS ( 1 H MRS) studies have reported reduced NAA in the frontal and temporal lobes and other structures of patients with SZ. However, a lesser number of studies report no difference in NAA between patients with SZ and healthy controls (HCs). What are the possible origins of the disparate findings? There are many potential sources of variance which may contribute to these conflicting results including differences in clinical and demographic characteristics (such as medication status or duration of illness), and also the choice of specific MRS acquisition parameters, techniques, and analytic methods (Sanches et al., 2004) . The fundamental principle underlying proton MRS is that for each MRS-visible metabolite, the fundamental frequency at which the nucleus of each hydrogen atom (proton) resonates is shifted by a small amount (measured in parts-per-million, ppm) from the basic resonant frequency of a single, isolated, proton. Chemically identical hydrogen nuclei within an MRS-visible metabolite experience similar local magnetic fields and nuclear spin-spin interactions and therefore have a characteristic chemical shift along the resonance frequency axis, which results in a spectral peak that is a chemical signature of that group of protons within that metabolite. The peak intensity or area under the spectral peak 
